Skip to main content

Table 2 Hematological toxicities ( n = 359 )

From: Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

Low Dose (n = 60) Total Grade 1 Grade 2 Grade 3 Grade 4
Leukopenia 13 (21.7%) 5 (8.3%) 6 (10%) 2 (3.3%) 0 (0%)
Anemia 33 (55.0%) 24 (40%) 9 (15%) 0 (0%) 0 (0%)
Thrombocytopenia 13 (21.7%) 8 (13.3%) 3 (5.0%) 2 (3.3%) 0 (0%)
Intermediate Dose ( n = 77 )      
Leukopenia 18 (23.4%) 9 (11.7%) 6 (7.8%) 3 (3.9%) 0 (0%)
Anemia 43 (55.8%) 35 (45.5%) 8 (10.4%) 0 (0%) 0 (0%)
Thrombocytopenia 23 (29.9%) 20 (26.0%) 2 (2.6%) 1 (1.3%) 0 (0%)
High Dose ( n = 222 )      
Leukopenia 77 (34.7%) 31 (14.0%) 31 (14.0%) 13 (5.9%) 2 (0.9%)
Anemia 145 (65.3%) 117 (52.7%) 22 (9.9%) 5 (2.3%) 0 (0%)
Thrombocytopenia 92 (41.4%) 68 (30.6%) 11 (5.0%) 6 (2.7%) 7 (3.2%)
  1. All toxicities are scored according to the NCI criteria.